Standout Papers

Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanc... 2013 2026 2017 2021 601
  1. Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial (2013)
    Florian Lordick, Yoon‐Koo Kang et al. The Lancet Oncology

Immediate Impact

82 standout
Sub-graph 1 of 19

Citing Papers

Cancer biomarkers: Emerging trends and clinical implications for personalized treatment
2024 Standout
Management of patients with advanced-stage HER2-positive breast cancer: current evidence and future perspectives
2024 Standout
3 intermediate papers

Works of G. Kurteva being referenced

Phase III, Randomized Study of Dual Human Epidermal Growth Factor Receptor 2 (HER2) Blockade With Lapatinib Plus Trastuzumab in Combination With an Aromatase Inhibitor in Postmenopausal Women With HER2-Positive, Hormone Receptor–Positive Metastatic Breast Cancer: Updated Results of ALTERNATIVE
2020

Author Peers

Author Last Decade Papers Cites
G. Kurteva 673 663 245 25 1.0k
Constantin Volovăț 755 640 265 43 1.3k
Jian Wu 564 746 283 29 1.3k
André M. Murad 732 929 368 21 1.1k
Claire Saffery 555 614 325 17 860
Kazuhiko Yonekura 761 617 291 23 1.3k
Hideyuki Ohshimo 993 704 315 17 1.4k
Isam Eltoum 522 497 439 26 1.2k
Luca Turati 824 418 467 18 1.1k
Yu-Hong Li 599 385 281 19 900
M. Lichinitser 659 389 607 24 1.3k

All Works

Loading papers...

Rankless by CCL
2026